Akero Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Akero Therapeutics, Inc. has completed its merger with Novo Nordisk A/S, becoming a wholly-owned subsidiary and delisting from Nasdaq.
Akero Therapeutics stockholders have approved the company's acquisition by Novo Nordisk A/S, with early termination of the HSR waiting period also granted.
Akero Therapeutics has agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash, including a contingent value right tied to efruxifermin's FDA approval.
Akero Therapeutics, Inc. has completed the voluntary early prepayment of its $37.6 million loan agreement with Hercules Capital, Inc., terminating the facility ahead of schedule.
Akero Therapeutics announced its second quarter 2025 financial results, highlighting significant progress in its EFX clinical program for MASH, including key data publications and presentations.
Akero Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 3, 2025, where shareholders approved the election of two Class III directors, ratified Deloitte & Touche LLP as auditors, and endorsed executive compensation.
8-K: Akero Therapeutics Announces Positive Phase 2b SYMMETRY Results and First Quarter 2025 Financials
Akero Therapeutics reports statistically significant reversal of compensated cirrhosis in Phase 2b SYMMETRY study and a strong cash position following a public offering.
Akero Therapeutics reports significant reversal of compensated cirrhosis in MASH patients treated with efruxifermin (EFX) and provides an update on its Phase 3 SYNCHRONY program.
Akero Therapeutics has successfully raised approximately $377.8 million through a public offering of common stock and pre-funded warrants, with the funds earmarked for clinical development and potential pipeline expansion.
Akero Therapeutics reports statistically significant reversal of compensated cirrhosis due to MASH with its drug candidate efruxifermin (EFX) in a Phase 2b study.
Akero Therapeutics reported its third quarter 2024 financial results and provided an update on its clinical programs, including the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study.
Akero Therapeutics reported its second quarter 2024 financial results, highlighted by the initiation of a Phase 3 trial for Efruxifermin (EFX) and expansion of its leadership team.
8-K: Akero Therapeutics Amends Charter to Limit Officer Liability, Elects Directors at Annual Meeting
Akero Therapeutics held its annual meeting, approving an amendment to its charter to limit officer liability and electing three directors.
Akero Therapeutics reported positive week 96 results from its Phase 2b HARMONY study and provided updates on its Phase 3 SYNCHRONY program, along with first quarter 2024 financial results.
Akero Therapeutics issued a warrant to Hercules Private Credit Fund 1 L.P. to purchase common stock as part of an amendment to their existing loan agreement.
Akero Therapeutics has entered into an underwriting agreement to sell 11 million shares of common stock at $29.00 per share, aiming to raise approximately $299.4 million to advance its clinical programs.
Akero Therapeutics' Phase 2b HARMONY study of efruxifermin (EFX) shows statistically significant improvements in liver fibrosis and other key endpoints at 96 weeks, particularly with the 50mg dose.
Akero Therapeutics reported its fourth quarter and full year 2023 financial results, along with updates on its Phase 3 clinical program for efruxifermin (EFX) in MASH.